Variables | n. (18) | % | |
---|---|---|---|
Site of oedema | Face | 14 | 77.8 |
Laryngeal | 8 | 44.4 | |
Eyes | 4 | 22.2 | |
Lips | 4 | 22.2 | |
Feet | 4 | 22.2 | |
Hand | 4 | 22.2 | |
The attacks associated with abdominal symptoms | yes | 14 | 77.8 |
no | 4 | 22.2 | |
Trigger of the attack | Trauma | 15 | 83.3 |
Spontaneous | 14 | 77.8 | |
Menstruation | 4 | 22.2 | |
stress | 1 | 5.6 | |
Severity Score | Mild | 3 | 16.7 |
Moderate | 4 | 22.2 | |
Severe | 11 | 61.1 | |
Variable | Mean ± SD | median(range) | |
Number of attacks per year | 23.7 ± 15.3 | 17(4–48) | |
Duration of angioedema attack (days) | 2.9 ± 1.5 | 2 (2–7) | |
Variables (treatment modalities) | n. (18) | % | |
Treatment during the attack | Antihistamine | 17 | 94.4 |
steroid | 15 | 83.3 | |
adrenaline | 1 | 5.6 | |
Plasma | 1 | 5.6 | |
Short-term prophylaxis | fresh frozen plasma | 4 | 22.2 |
Long-term prophylaxis | Danazol | 7 | 38.9 |
Danazol/(human C1 esterase inhibitor) | 1 | 5.6 |